Meta-Analysis of CYP1B1 Polymorphisms and Prostate Cancer.

<p>CYP1B1, cytochrome P450 1B1; OR, odds ratio; CI, confidence interval. Ph, P value for heterogeneity; PB, population based; HB, hospital based;</p

The flow diagram for the review process and outcomes of inclusion and exclusion.

<p>The flow diagram for the review process and outcomes of inclusion and exclusion.</p

Egger’s linear regression test to measure the funnel plot asymmetry.

<p>Egger’s linear regression test to measure the funnel plot asymmetry.</p

Main characteristics of studies included in this meta-analysis.

<p>Main characteristics of studies included in this meta-analysis.</p

Association of SMAD7 rs12953717 Polymorphism with Cancer: A Meta-Analysis

<div><p>Background</p><p>Accumulating evidence has suggested that Mothers against decapentaplegic homolog 7 (SMAD7) rs12953717 polymorphism might be related to cancer risk. However, epidemiologic findings have been inconsistent. We therefore performed a meta-analysis to clarify the association between the SMAD7 rs12953717 polymorphism and cancer risk.</p> <p>Methods</p><p>A comprehensive search was conducted to identify all eligible studies of SMAD7 rs12953717 polymorphism and cancer risk. We used odds ratios (ORs) to assess the strength of the association, and 95% confidence intervals (CIs) to give a sense of the precision of the estimate. Heterogeneity, publication bias, and sensitivity analysis were also explored.</p> <p>Results</p><p>A total of 14 case-control studies, including 16928 cases and 14781 controls, were included in the present meta-analysis. The overall results showed that the variant genotypes were associated with a significantly increased risk of all cancer types (homozygote comparison, OR = 1.23, 95%CI = 1.10–1.38, P<0.01; heterozygote comparison, OR = 1.12, 95%CI = 1.02–1.22, P = 0.02; recessive model, OR = 1.17, 95%CI = 1.07–1.29, P<0.01; dominant model, OR = 1.15, 95%CI = 1.06–1.25, P<0.01; allelic model, OR = 1.12, 95%CI = 1.06–1.18, P<0.01). Further sensitivity analysis confirmed the significant association. In the subgroup analysis by ethnicity, SMAD7 rs12953717 polymorphism was significantly associated with cancer risk in both Caucasians and Asians. In the subgroup analysis by cancer types, SMAD7 rs12953717 polymorphism was significantly associated with colorectal cancer.</p> <p>Conclusions</p><p>Our investigations demonstrate that rs12953717 polymorphism is associated with the susceptibility of cancer. Large-scale and well-designed case-control studies are necessary to validate the risk identified in the present meta-analysis.</p> </div

Meta-Analysis of MTHFD1 Gene Polymorphisms and Cancer.

<p>OR, odds ratio; CI, confidence interval.</p

Meta-Analysis of SMAD7 rs12953717 Polymorphism and Cancer.

<p>SMAD7, Mothers against decapentaplegic homolog 7; OR, odds ratio; CI, confidence interval.</p

Association of Methylenetetrahydrofolate Dehydrogenase 1 Polymorphisms with Cancer: A Meta-Analysis

<div><p>Background</p><p>Studies investigating the association between single-nucleotide polymorphisms (SNPs) of the methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) and cancer risk report conflicting results. To derive a more precise estimation of the relationship between MTHFD1 polymorphisms and cancer risk, the present meta-analysis was carried out.</p><p>Methodology/Principal Findings</p><p>A comprehensive search was conducted to determine all the eligible studies about MTHFD1 polymorphisms and cancer risk. Combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association between the MTHFD1 polymorphisms and cancer risk. We investigated by meta-analysis the effects of 2 polymorphisms in MTHFD1: G1958A (17 studies, 12348 cases, 44132 controls) and G401A (20 studies, 8446 cases, 14020 controls). The overall results indicated no major influence of these 2 polymorphisms on cancer risk. For G1958A, a decreased cancer risk was found in acute lymphoblastic leukemia (ALL)/Asians (the dominant: OR = 0.74, 95% CI = 0.58–0.94, P = 0.01; allelic: OR = 0.80, 95% CI = 0.65–0.99, P = 0.04) and other cancers (recessive: OR = 0.80, 95% CI = 0.66–0.96, P = 0.02). For G401A, the data showed that MTHFD1 G401A polymorphism was associated with a decreased colon cancer risk under dominant model (OR = 0.89, 95% CI = 0.80–0.99, P = 0.04).</p><p>Conclusions</p><p>The results suggest that MTHFD1 G1958A polymorphism might be associated with a decreased risk of ALL and other cancers. Meanwhile, the MTHFD1 G401A might play a protective role in the development of colon cancer. Large-scale and well-designed case-control studies are necessary to validate the risk identified in the present meta-analysis.</p></div

Additional file 4: Figure S1. of miR-539 inhibits prostate cancer progression by directly targeting SPAG5

miR-539 inhibits PCa cell proliferation, migration and invasion by targeting SPAG5 in vitro. A, Ectopic expression of miR-539 can mimic the suppression of colony formation induced by SPAG5 knockdown in PC-3 and LNCaP cells; B, Ectopic expression of miR-539 can mimic the suppression of migration activity induced by SPAG5 knockdown in PC-3 and LNCaP cells; C, Ectopic expression of miR-539 can mimic the suppression of invasion activity induced by SPAG5 knockdown in PC-3 and LNCaP cells; D, The efficiency of SPAG5 knockdown and ectopic expression of miR-539 was confirmed at protein level by western blot. (JPG 145 kb

Additional file 5: Figure S2. of miR-539 inhibits prostate cancer progression by directly targeting SPAG5

miR-539 is downexpressed in primary PCa and metastatic PCa. miR-539 level was gradually decreased in normal prostate, primary PCa, and metastatic PCa samples. (JPG 173 kb